--(BUSINESS WIRE)-- Sucampo Pharmaceuticals, Inc. ("Sucampo" or "the Company") (NAS: SCMP) today announced that it has received approval of an sNDA for RESCULA ® (unoprostone isopropyl ophthalmic ...

As part of this program, R-Tech Ueno, Sucampo’s development partner, has signed an agreement for unoprostone isopropyl with the JST in which the Japanese government shall provide the majority of ...

Review the side-effects of Unoprostone as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

Discover comprehensive details about Unoprostone, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated ...

"We are very pleased to receive orphan drug designation by the EMA for unoprostone isopropyl for the treatment of RP," said Ryuji Ueno, M.D., Ph.D., Ph.D., Chairman, Chief Executive Officer ...

(1) Background and Outlines 1) We entered into, on April 23 th, 2009, Unoprostone NDA Transfer, Patent and Know-how Licensing, and Data Sharing Agreement, as well as Exclusive Manufacturing and ...

The appearance frequency of eyelid pigmentation was similar among the five types of PG analogs studied, and eyelash bristles appeared less frequently with isopropyl unoprostone use. Patients are ...

today announced that its development partner, R-Tech Ueno, Ltd. (R-Tech), completed the enrollment on-time for a Phase 3 study of unoprostone isopropyl ophthalmic solution 0.15% for the treatment ...

Sucampo Announces FDA Approval of an sNDA for RESCULA® (unoprostone isopropyl) Sucampo Will Begin Commercializing RESCULA in First Quarter of 2013 BETHESDA, Md.--(BUSINESS WIRE)-- Sucampo ...

Sucampo Pharmaceuticals Achieves Orphan Designation for Unoprostone Isopropyl for Treatment of Retinitis Pigmentosa by European Medicines Agency BETHESDA, Md.--(BUSINESS WIRE)-- Sucampo ...

Sucampo Pharmaceuticals Achieves Orphan Designation for Unoprostone Isopropyl for Treatment of Retinitis Pigmentosa by European Medicines Agency BETHESDA, Md.--(BUSINESS WIRE)-- Sucampo ...